Physician profile
Jaspreet Mann
NPI 1184006280
$905.19
in general payments reported to CMS, 2019-2025
15 companies · $92.00 in 2025
The $92.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $15.34 · 2021: $193 · 2022: $244 · 2023: $75.32 · 2024: $141 · 2025: $92.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $308.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $184.74 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $122.84 | 2021-2022 | |
| Lilly USA, LLC | $122.37 | 2024 | Zepbound |
| Abbvie INC. | $118.22 | 2021-2023 | |
| Alkermes, INC. | $84.42 | 2019-2023 | Vivitrol |
| Biohaven Pharmaceutical Holding Company Ltd. | $67.68 | 2022 | |
| Exact Sciences Corporation | $57.65 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $35.06 | 2022-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2025 | |
| Philips North America LLC | $17.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2022 | |
| Antares Pharma, INC. | $16.16 | 2025 | Xyosted |
| Allergan, INC. | $15.34 | 2020 | |
| Acadia Pharmaceuticals INC | $14.74 | 2025 | Daybue |
| Novartis Pharmaceuticals Corporation | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.